Podcast
Questions and Answers
Which of the following is NOT true about the opioid epidemic?
Which of the following is NOT true about the opioid epidemic?
- The opioid epidemic is driven by the widespread use and abuse of opiates and opioids. (correct)
- The introduction of oxycodone by Purdue Pharma as a supposed solution for pain management marked the beginning of the opioid epidemic.
- The medical community's shift towards aggressive pain treatment in the 1990s contributed to the rapid increase in prescription narcotics and opiates.
- Opiates are derived from the poppy plant, while opioids are synthetic drugs created in a lab.
Which company faced backlash for misleading doctors about drug addiction during the opioid epidemic?
Which company faced backlash for misleading doctors about drug addiction during the opioid epidemic?
- Johnson & Johnson
- Merck & Co.
- Purdue Pharma (correct)
- Bayer
What is the main concern expressed in the video regarding the drug sufentanil?
What is the main concern expressed in the video regarding the drug sufentanil?
- Its approval in 2018 may worsen the ongoing opioid epidemic. (correct)
- It is over 10 times more powerful than fentanyl.
- It is mainly used in labor and delivery and end-stage cancer treatment.
- Its potency and ease of smuggling make it attractive to drug cartels.
Which publication in 2000 emphasized the importance of measuring and treating pain at every doctor's visit?
Which publication in 2000 emphasized the importance of measuring and treating pain at every doctor's visit?
What was Purdue Pharma's response to the increase in prescription pain medications and their addictive nature?
What was Purdue Pharma's response to the increase in prescription pain medications and their addictive nature?
What was the flaw in Purdue Pharma's plan with the introduction of oxycodone?
What was the flaw in Purdue Pharma's plan with the introduction of oxycodone?
What is the concern expressed by the speaker about the approval of sufentanil?
What is the concern expressed by the speaker about the approval of sufentanil?